Evommune reported Phase 2a results for EVO301 that met the trial’s primary endpoint, producing substantial EASI score improvements versus placebo and prompting a sharp rise in the company’s shares. The data showed rapid, clinically meaningful skin clearance at Week 12 and set the stage for a Phase 2b subcutaneous program. Nektar released one‑year maintenance data showing its IL‑2 pathway agent, rezpegaldesleukin (rezpeg), sustained or deepened skin‑clearance responses after patients transitioned to less‑frequent dosing. Nektar plans Phase 3 testing and said the maintenance profile could provide a competitive advantage on dosing frequency and durable response.